TW200509993A - Process for forming amorphous atorvastatin - Google Patents
Process for forming amorphous atorvastatinInfo
- Publication number
- TW200509993A TW200509993A TW093116683A TW93116683A TW200509993A TW 200509993 A TW200509993 A TW 200509993A TW 093116683 A TW093116683 A TW 093116683A TW 93116683 A TW93116683 A TW 93116683A TW 200509993 A TW200509993 A TW 200509993A
- Authority
- TW
- Taiwan
- Prior art keywords
- amorphous atorvastatin
- forming amorphous
- atorvastatin
- solvent
- forming
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791603P | 2003-06-12 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200509993A true TW200509993A (en) | 2005-03-16 |
Family
ID=33551779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093116683A TW200509993A (en) | 2003-06-12 | 2004-06-10 | Process for forming amorphous atorvastatin |
Country Status (10)
Country | Link |
---|---|
US (1) | US7655692B2 (zh) |
EP (1) | EP1635789A1 (zh) |
JP (1) | JP2006527261A (zh) |
AR (1) | AR044659A1 (zh) |
BR (1) | BRPI0411313A (zh) |
CA (1) | CA2465640C (zh) |
CL (1) | CL2004001426A1 (zh) |
MX (1) | MXPA05012954A (zh) |
TW (1) | TW200509993A (zh) |
WO (1) | WO2004110407A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110446705A (zh) * | 2017-03-30 | 2019-11-12 | 默克专利股份公司 | (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
EP1614412A1 (de) † | 2003-11-18 | 2006-01-11 | Helm AG | Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten |
KR20070106680A (ko) * | 2004-09-30 | 2007-11-05 | 닥터 레디스 레보러터리즈 리미티드 | 비정질 아토르바스타틴 칼슘 |
MX2007004425A (es) * | 2004-10-18 | 2007-06-07 | Teva Pharma | Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. |
US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
EP1963263A4 (en) * | 2005-11-29 | 2009-09-02 | Biocon Ltd | POLYMORPHS OF A MAGNESIUM SALT (2: 1) OF ACID [R- (R *, R *)] - 2- (4-FLUOROPHENYL) -BETA, DELTA-DIHYDROXY-5- (L-METHYLETHYL) - 3-PHENYL-4 - [(phenylamino) carbonyl] -LH-PYRROLE-L-heptanoic |
EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
AU2007300071A1 (en) * | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
WO2008129562A2 (en) * | 2007-04-20 | 2008-10-30 | Morepen Laboratories Limited | An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof |
EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
US20110064816A1 (en) * | 2008-05-13 | 2011-03-17 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
WO2011017297A2 (en) | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
EP2779999A2 (en) | 2011-11-15 | 2014-09-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5297627A (en) * | 1989-10-11 | 1994-03-29 | Mobil Oil Corporation | Method for reduced water coning in a horizontal well during heavy oil production |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
CA2150372C (en) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
SI0848705T1 (en) | 1995-07-17 | 2002-04-30 | Warner-Lambert Company | Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
US5998633A (en) | 1996-07-29 | 1999-12-07 | Warner-Lambert Company | Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid |
WO1999032434A1 (en) | 1997-12-19 | 1999-07-01 | Warner-Lambert Export Limited | Process for the synthesis of 1,3-diols |
ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
IN191236B (zh) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
ES2349364T3 (es) | 1999-11-17 | 2010-12-30 | Teva Pharmaceutical Industries, Ltd. | Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica. |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6531507B1 (en) | 2000-06-09 | 2003-03-11 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
EP1332130A4 (en) | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
PL362981A1 (en) | 2000-11-16 | 2004-11-02 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
IT1320176B1 (it) | 2000-12-22 | 2003-11-26 | Nicox Sa | Dispersioni solide di principi attivi nitrati. |
HUP0302519A3 (en) | 2000-12-27 | 2008-10-28 | Teva Pharma | Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them |
US6476235B2 (en) | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
WO2002062824A2 (en) | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid ? precursor disorder |
IN190564B (zh) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
UA74075C2 (en) | 2001-06-29 | 2005-10-17 | Warner Lambert Co | NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS) |
JP2005500351A (ja) | 2001-07-30 | 2005-01-06 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 結晶形態viおよびviiのアトルバスタチンカルシウム |
WO2003018547A2 (en) | 2001-08-31 | 2003-03-06 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
EP1480950A4 (en) | 2002-02-15 | 2005-05-18 | Teva Pharma | NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX |
CZ2004943A3 (cs) | 2002-03-18 | 2005-02-16 | Biocon Limited | Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic |
CA2491051A1 (en) | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
-
2004
- 2004-04-20 US US10/828,488 patent/US7655692B2/en active Active
- 2004-04-29 CA CA002465640A patent/CA2465640C/en not_active Expired - Fee Related
- 2004-06-01 MX MXPA05012954A patent/MXPA05012954A/es unknown
- 2004-06-01 JP JP2006516513A patent/JP2006527261A/ja not_active Abandoned
- 2004-06-01 BR BRPI0411313-6A patent/BRPI0411313A/pt not_active IP Right Cessation
- 2004-06-01 EP EP04735622A patent/EP1635789A1/en not_active Withdrawn
- 2004-06-01 WO PCT/IB2004/001879 patent/WO2004110407A1/en active Application Filing
- 2004-06-08 CL CL200401426A patent/CL2004001426A1/es unknown
- 2004-06-10 TW TW093116683A patent/TW200509993A/zh unknown
- 2004-06-10 AR ARP040102007A patent/AR044659A1/es unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110446705A (zh) * | 2017-03-30 | 2019-11-12 | 默克专利股份公司 | (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式 |
CN110446705B (zh) * | 2017-03-30 | 2023-04-14 | 默克专利股份公司 | (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式 |
Also Published As
Publication number | Publication date |
---|---|
CA2465640A1 (en) | 2004-12-12 |
JP2006527261A (ja) | 2006-11-30 |
US7655692B2 (en) | 2010-02-02 |
US20050032880A1 (en) | 2005-02-10 |
WO2004110407A1 (en) | 2004-12-23 |
CA2465640C (en) | 2008-07-15 |
BRPI0411313A (pt) | 2006-07-11 |
EP1635789A1 (en) | 2006-03-22 |
AR044659A1 (es) | 2005-09-21 |
MXPA05012954A (es) | 2006-02-13 |
CL2004001426A1 (es) | 2005-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200509993A (en) | Process for forming amorphous atorvastatin | |
WO2006015081A3 (en) | A PROCESS FOR THE PREPARATION OF 7α-ALKYLATED 19-NORSTEROIDS | |
AU2003241813A1 (en) | Process for producing nanoparticle and nanoparticle produced by the process | |
EP1763703A4 (en) | MANUFACTURING METHOD, SUCH AS A THREE DIMENSIONAL PRINTING, INCLUDING FORMATION OF FILMS USING SOLVENT VAPOR AND THE LIKE | |
EP1607446A4 (en) | ORGANIC INORGANIC HYBRID MATERIAL, COMPOSITION FOR ITS SYNTHESIS AND METHOD FOR PRODUCING THE HYBRID MATERIAL | |
CA2560252A1 (en) | Process for the production of atorvastatin calcium in amorphous form | |
EP1960402A4 (en) | NEW IMIDAZOCHINAZOLINE DERIVATIVE, METHOD FOR ITS MANUFACTURE AND ORGANIC ELECTRONIC DEVICE THEREOF USING THIS | |
WO2006127941A3 (en) | Amorphous cinacalcet hydrochloride and preparation thereof | |
EP1839501A4 (en) | SITOSTEROL-CONTAINING COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF | |
AU2003242046A1 (en) | Sustained-release composition, process for producing the same and preparation thereof | |
EP1724272A4 (en) | POLYCYCLIC ORGANIC SUBSTANCE WITH FUSED RING CONTAINING CHALCOGENURE AND PROCESS FOR PRODUCING THE SAME | |
WO2007075870A3 (en) | Processes for taxane derivatives and intermediates useful therein | |
AU2003292837A1 (en) | Process for producing polymer | |
TW200624419A (en) | Process for forming amorphous atorvastatin | |
WO2006117763A3 (en) | A process for the preparation of doripenem | |
AU2003266516A1 (en) | Resin compositions, composites made by using the same, and process for production thereof | |
AU2001242817A1 (en) | Photocurable composition, cured object, and process for producing the same | |
EP1870438A4 (en) | PHTHALOCYANINE DERIVATIVE, PROCESS FOR THE SYNTHESIS OF SAID DERIVATIVE, AND COLORED PREPARATIONS CONTAINING SAID PHTHALOCYANINE DERIVATIVE | |
AU2003275675A1 (en) | Process for producing hexahydrofurofuranol derivative, intermediate thereof and process for producing the same | |
AU2003211600A1 (en) | Process for producing proanthocyanidin-rich material | |
AU2003292763A1 (en) | Process for producing microsphere and apparatus for producing the same | |
AU2003231482A1 (en) | Process for producing lactide | |
AR048756A1 (es) | Procedimiento para formar atorvastatina amorfa | |
AU2003275547A1 (en) | Process for producing copolyester | |
AU2003211279A1 (en) | Process for producing proanthocyanidine-rich material |